Diagnosis or prognosis of lung cancer and colorectal cancer based on expression level of glutaredoxin 3
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 8, 2015
Grant Date -
Jan 19, 2012
app pub date -
Apr 15, 2009
filing date -
Apr 8, 2009
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to a biomarker for diagnosing lung cancer and colorectal cancer containing glutaredoxin 3 as an active ingredient, and a kit for diagnosing lung cancer and colorectal cancer using the same biomarker. Glutaredoxin 3 of the present invention is over-expressed in lung cancer tissue and colorectal cancer tissue, which enables early prediction of diagnosis or prognosis of lung cancer and colorectal cancer. Thus, glutaredoxin 3 can be helpfully used as a biomarker for diagnosing lung cancer and colorectal cancer.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully